Drama continues to unfold following the FDA’s controversial approval of a new Alzhiemer’s treatment. Members of the FDA’s advisory committee voted against approval, and some members resigned in protest. But how does this impact you or loved ones with chronic disease?
On this episode: Peter Pitts, a former FDA Associate Commissioner, who previously oversaw the committee process. He explains how the committees make recommendations on new and emerging treatments and drugs for rare and chronic diseases. And how reforms to strict conflict of interest rules could bring more patient voices to the table.
Plus, Field Correspondent Kate Pecora speaks with lung cancer survivor Jeff Julian on overcoming the odds and his search to find the best treatment for him.
Dr. Robert Goldberg, “Dr. Bob,” Co-Founder and Vice President of the Center for Medicine in the Public Interest
Kate Pecora, Field Correspondent, Patients Rising
Peter Pitts, President and Co-Founder, Center for Medicine in the Public Interest
Jeff Julian, Cancer Advocate
Jody Quinn, Patient Correspondent
The successful patient is one who can get what they need when they need it. We all know insurance slows us down, so why not take matters into your own hands? Our Navigator is an online tool that allows you to search a massive network of health-related resources using your zip code so you get local results. Get proactive and become a more successful patient right now at PatientsRisingConcierge.org
Have a question or comment about the show, or want to suggest a show topic or share your story as a patient correspondent?
Drop us a line: email@example.com
The views and opinions expressed herein are those of the guest(s)/ author(s) and do not reflect the official policy or position of Patients Rising.